Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGarrido, Pilar
dc.contributor.authorAdjei, A. A.
dc.contributor.authorBajpai, J.
dc.contributor.authorBerghoff, A. S.
dc.contributor.authorChoo, S. P.
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorGarralda Cabanas, Elena
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorBanerjee, Susana
dc.date.accessioned2022-02-23T06:49:57Z
dc.date.available2022-02-23T06:49:57Z
dc.date.issued2021-06
dc.identifier.citationGarrido P, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, et al. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021 Jun;6(3):100131.
dc.identifier.issn2059-7029
dc.identifier.urihttps://hdl.handle.net/11351/7072
dc.descriptionCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV Inequalities; Woman
dc.description.abstractBackground European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects of the COVID-19 pandemic on women, the ESMO W4O Committee initiated a study on the impact of the pandemic on the lives of female and male oncologists. Methods A questionnaire was sent to ESMO members and put on the ESMO website between 8 June 2020 and 2 July 2020. Questions focused on the working (hospital tasks, laboratory tasks, science) and home (household management, childcare, parent care, personal care) lives of oncologists during and after COVID-19-related lockdowns. Results Of 649 respondents, 541 completed the questionnaire. Of these, 58% reported that COVID-19 had affected their professional career, 83% of whom said this was in a negative way (85% of women versus 76% of men). Approximately 86% reported that COVID-19 had changed their personal life and 82% their family life. Women were again significantly more affected than men: personal life (89% versus 78%; P = 0.001); family life (84% versus 77%; P = 0.037). During lockdowns, women reported increased time spent on hospital and laboratory tasks compared with men (53% versus 46% and 33% versus 26%, respectively) and a significantly higher proportion of women than men spent less time on science (39% versus 25%) and personal care (58% versus 39%). After confinement, this trend remained for science (42% versus 23%) and personal care (55% versus 36%). Conclusions The COVID-19 pandemic has adversely affected the professional and home lives of oncologists, especially women. Reduced research time for female oncologists may have long-lasting career consequences, especially for those at key stages in their career. The gender gap for promotion to leadership positions may widen further as a result of the pandemic.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesESMO Open;6(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPandèmia de COVID-19, 2020-
dc.subjectOncologia
dc.subjectQüestionaris
dc.subject.meshCoronavirus Infections
dc.subject.meshOncologists
dc.subject.meshSurveys and Questionnaires
dc.titleHas COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.esmoop.2021.100131
dc.subject.decsinfecciones por Coronavirus
dc.subject.decsoncólogos
dc.subject.decsencuestas y cuestionarios
dc.relation.publishversionhttps://doi.org/10.1016/j.esmoop.2021.100131
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Garrido P] Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Adjei AA] Mayo Clinic, Rochester, USA. [Bajpai J] Tata Memorial Centre, Mumbai, India. [Banerjee S] The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK. [Berghoff AS] Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria. [Choo SP] Curie Oncology Singapore, National Cancer Centre Singapore, Singapore. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Thoracic Oncology and H&N Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, Barcelona, Spain. [Garralda E] Early Drug Development Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, Barcelona, Spain
dc.identifier.pmid34144778
dc.identifier.wos000663044500027
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record